Q32 Bio vs Roivant Sciences
QTTB and ROIV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How QTTB and ROIV compare
Roivant Sciences is the larger company, worth 110 times as much as Q32 Bio ($28.6B against $259M).
Q32 Bio scores higher on the StockData Score (11 against 8 for Roivant Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | QTTB | ROIV |
|---|---|---|
| Size and price | ||
| Market cap | $259M | $28.6B |
| Share price | $8.71 | $39.53 |
| Change, 1 year | 258% | 85.4% |
| Change, 5 years | −90.6% | 394% |
| Beta (5Y) | 0.67 | 0.85 |
| Employees | 24 | 721 |
| StockData Score | ||
| Total score | 11 (better) | 8 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 | 1 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 695× |
| P/B | 0.9× (better) | 7.1× |
| EV/EBITDA | −1.6× | – |
| FCF yield | – | −0.12% |
| Fair value | $20.33 | – |
| Margin of safety | 57.1% | – |
| Growth | ||
| Revenue growth (TTM) | – | 102% |
| Revenue growth, 5Y average | 81.9% (better) | −19.1% |
| Profitability | ||
| Operating margin | – | −1358% |
| Net margin | – | −838% |
| FCF margin | – | −81.2% |
| Return on equity | 24.0% (better) | −8.2% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 56.34 (better) | 15.56 |
| Altman Z-score | 16.60 | 45.37 (better) |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −4.0% | – |
| Shareholder yield | −4.0% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 74.6% | 78.1% |
| Held by insiders | 28.9% | 13.9% |
| Insider net buying, 12 months | $29.5M (better) | −$798M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 26.4% | 7.3% |
Go deeper
- QTTB stock overview
- QTTB income statement
- QTTB valuation and score
- ROIV stock overview
- ROIV income statement
- ROIV valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.